Despite its convenience and simplicity, use of only sliding-scale insulin therapy in inpatient settings has been demonstrated to be worse for glycemic control compared with basal–bolus therapy and is strongly discouraged in the current American Diabetes Association guidelines23. The gene discussed is INS; the disease is diabetes mellitus.